Table of Contents
Introduction
Overview of Schizophrenia
- Disease Symptoms, Onset, and Prevalence
- Pathophysiology and Risk Factors for Schizophrenia
Current Therapies for Schizophrenia
- Typical Antipsychotics
- Atypical Antipsychotics
- A Side-by-Side Comparison: Results from the Clinical Antipsychotic Trials
of Intervention
- Effectiveness (CATIE)
Emerging Therapies for Schizophrenia
- Serotonin and Dopamine Receptor Antagonists
- H. Lundbeck's Serdolect
- Dainippon Sumitomo Pharmaceuticals' Blonanserin
- Johnson & Johnson's Paliperidone
- Organon/Pfizer's Asenapine
- Vanda Pharmaceuticals' Iloperidone
- Dopamine Partial Agonists
- Serotonin Inverse Agonists
- Novel Agents
- Neurokinin Receptor Antagonists
- AMPA Receptor Modulators
- Secretin Antagonists
Current Market and Future Prospects for Schizophrenia Therapies
| 
View Cart
